First-Line [<sup>177</sup>Lu]Lu-PSMA-617 Therapy Without ADT, Chemotherapy, or Local Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
Where this comes from
- Record sourced from PubMed, PMID 40998725.
- Also identified by DOI 10.2967/jnumed.125.270704 and PMC identifier 12582190.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The treatment of metastatic prostate cancer relies on the use of androgen deprivation therapy, which is associated with many side effects, including adverse cardiovascular outcomes. <sup>177</sup>Lu-vipivotide tetraxetan ([<sup>177</sup>Lu]Lu-PSMA-617) is used in the treatment of prostate-specific membrane antigen-expressing metastatic castration-resistant prostate adenocarcinoma. We present the case of a patient with prostate cancer with numerous metastatic lesions who declined androgen deprivation therapy, chemotherapy, and local therapy to the prostate gland and instead received first-line systemic [<sup>177</sup>Lu]Lu-PSMA-617. He exhibited a significant response in both the primary cancer and its metastatic foci after 2 doses of the treatment.
Medical subject headings
- Lutetium
- Prostatic Neoplasms
- Prostate-Specific Antigen